Glenn S. Murphy, Joseph W. Szokol, Michael J. Avram, Steven B. Greenberg, Torin D. Shear, Mark A. Deshur, Jeffery S. Vender, Jessica Benson, Rebecca L. Newmark
5 min
Posterior spinal fusion surgery is associated with intense postoperative pain, often complicated by preexisting neuropathic pain or opioid tolerance. Traditional management with intermediate-duration opioids like hydromorphone often results in significant fluctuations in serum opioid levels, leading to inadequate pain control or adverse side effects. This randomized, double-blinded, controlled trial evaluated whether the long-duration opioid methadone, administered intraoperatively, could improve postoperative outcomes compared to standard hydromorphone.
The researchers enrolled 120 patients undergoing elective posterior spinal fusion. Participants were randomized to receive either 0.2 mg/kg of methadone at the start of surgery or 2 mg of hydromorphone at the conclusion of the procedure. The primary outcome was the total consumption of intravenous hydromorphone on the first postoperative day (POD 1). Secondary outcomes included pain scores (at rest, with movement, and with coughing), overall patient satisfaction, and the incidence of opioid-related adverse events (such as respiratory depression, nausea, and vomiting) through POD 3.
The study found that patients who received intraoperative methadone required significantly less intravenous hydromorphone on POD 1 (4.56 mg vs. 9.90 mg) and continued to require less opioid medication on PODs 2 and 3. Furthermore, the methadone group reported lower pain scores at most assessment points and higher overall satisfaction with pain management. Importantly, there were no significant differences between the groups regarding the incidence of opioid-related adverse events, such as hypoventilation or hypoxemia, suggesting that the long-acting opioid was safe under the study conditions.
This study provides evidence that a single intraoperative dose of methadone can serve as an effective, long-acting analgesic strategy for complex spinal surgeries. By reducing the need for frequent rescue doses of short-acting opioids, methadone may help stabilize pain management during the critical early postoperative period, potentially improving the patient experience without increasing the risk of respiratory complications.
Alex: And the effect didn't just hold on day one?
Sam: That's where the supporting evidence gets interesting. The reduction in rescue opioid requirements persisted into the second and third postoperative days. That's not what you'd expect if this were purely a pharmacokinetic story about drug duration. It suggests the preemptive NMDA blockade is genuinely altering the recovery trajectory, not just delaying the pain.
Alex: Though I'd imagine a careful referee would push back on the design here. The groups didn't receive their drugs at the same time point.
Sam: That's the central limitation, and the authors are transparent about it. Methadone was given at induction; hydromorphone was given at closure. That timing difference is a genuine confound. You can't fully isolate whether the benefit comes from the drug's pharmacological profile—the NMDA antagonism, the long half-life—or simply from having a stable analgesic concentration in place from the very first incision.
Alex: So we can't cleanly attribute the effect to the molecule versus the preemptive timing.
Sam: Exactly. The authors defend the design on clinical grounds, which is reasonable. Giving hydromorphone at induction would have left patients in agony in the PACU given its short half-life, and giving methadone at closure would have introduced genuine respiratory risk. They chose the protocol that was both safe and feasible. But that trade-off means the mechanistic attribution stays somewhat open. A cleaner design would require a third arm—methadone at closure, for instance—which they didn't include.
Alex: So what does this leave unresolved for the field?
Sam: The most pressing gap is dose-response optimization. The study uses what the authors describe as "common" doses, but there's no standardized weight-based protocol for this patient population—and spinal fusion patients often arrive with significant baseline opioid tolerance. We don't yet know whether the effect size holds, shrinks, or needs to be amplified in high-tolerance patients. Future work needs to move toward personalized dosing, potentially indexed to preoperative opioid exposure. If that can be dialed in, the authors suggest we might eventually reach a point where PCA devices become unnecessary for these procedures entirely.
Alex: That's a substantial claim. Moving from reactive, high-volatility rescue opioid management to a stable, preemptive pharmacological bridge—and potentially removing the PCA from the equation altogether.
Sam: It is, and the current evidence supports the direction even if it doesn't yet close the case. The load-bearing finding—that a single intraoperative methadone dose meaningfully reduces rescue opioid requirements without adding adverse events—is solid. The mechanism is plausible and internally consistent. What's still needed is the dose-optimization work and a design that can more cleanly separate timing from pharmacology.
Alex: A clear result with a well-defined next question. That's a good place to leave it. Thanks for listening to ResearchPod.